Eric Rowinsky

Tapestry Pharmaceuticals, Inc. develops, manufactures, and markets an anti-cancer pharmaceutical called Paclitaxel. It focuses on the development of proprietary therapies for the treatment of cancer, new products and technologies may involve the examination of individual molecules and classes of compounds. The company was founded in 1991 and is headquartered in Ankeny, IA.

Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA.

DNIB Unwind, Inc. develops biopharmaceutical preparations. The company was founded by Omid C. Farokhzad and Robert S. Langer on May 19, 2006 and is headquartered in Los Angeles, CA.

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY.

ImmuneXcite, Inc. operates as a biopharmaceutical company which develops monoclonal antibodies for cancer. The firm provides nivel immuno-incology technology platform, which leverages both the innate and adaptive immune responses to selectively treat a wide range of tumor types. The company was Ifat Rubin-Bejerano, Gerald R. Fink and Yaniv Bejerano and is headquartered in Waltham, MA.

National Cancer Institute provides healthcare services. It specializes in different cancer treatment such as adrenocortical carcinoma, anal cancer, appendix cancer, skin cancer, breast cancer, cardiac tumors, endometrial cancer, and gallbladder cancer. The company was founded in March 1937 and is headquartered in Bethesda, MD.

Founded in 2004, Biogen Idec New Ventures is the corporate venture group of Biogen Idec, Inc. In 2003, Biogen and IDEC Pharmaceuticals merged to create Biogen Idec, Inc. (NASDAQ: BIIB)

Part of Biogen, Inc., Biogen Idec, Inc. (North Carolina) is a pharmaceutical company based in Durham, NC. The private company develops pharmaceutical products. Michel Pericles Vounatsos has been the CEO of the company since 2016.

DLVR Therapeutics, Inc. operated as a biotechnology company which developed oncology therapeutics. The company was headquartered in Toronto, Canada.

Cage Pharma, Inc. operates as a developmental stage bio-pharmaceutical company. It focuses on developing anti-cancer drugs. The company was founded on October 24, 2008 by Jean–Francois H. Geschwind and is headquartered in Potomac, MD.

Inspirna, Inc. operates as a clinical stage biopharmaceutical company which develops molecule and antibody cancer therapeutics. It provides drugs for melanoma, colorectal and triple-negative breast cancers. The firm identifies novel cancer targets using a microRNA based target discovery platform that enable the identification and validation of novel post-transcriptionally regulated targets. The company was founded by Masoud Tavazoie, Sohail Tavazoie, Shahram Seyedin-Noor and Saeed Tavazoie in 2010 and is headquartered in New York, NY.

BioXcel Corp. is a biopharmaceutical company based in Branford, CT that utilizes advanced technologies such as AI to develop transformative medicines at unprecedented speed in multiple therapeutic areas with high unmet needs. BioXcel's AI-enabled platform, EvolverAI, helps reduce development costs and accelerates the drug development timelines for a technologically-enabled, fast and efficient drug discovery process. The private company's family of companies includes BioXcel Therapeutics, Inc., which is a biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing AI and its approaches. BioXcel is deeply involved in creating breakthroughs in various categories of diseases. The company was founded by Vimal D. Mehta and Krishnan Nandabalan, with Vimal D. Mehta serving as the CEO since incorporation.

IDD, Inc. specializes in custom software solutions, web design, mobile applications, media services, graphic design, digital and print marketing. The company is headquartered in Blacksburg, VA.

Tusk Therapeutics Ltd. operates as a immuno-oncology company, focused on discovering and developing therapeutic antibodies. It provides immune modulating cancer therapeutics. The company is headquartered in Stevenage, the United kingdom.

Clearpath Development Co. provides biopharmaceutical companies with an alternative mechanism for accelerating product development. The private company is based in Rockville.

Oncotartis, Inc. operates as a biotechnology company. The company was founded by Andrei Gudkov, Alexander Polinsky and Olga Chernova in 2011 and is headquartered in Buffalo, NY.

Founded in 2003, Maxwell Asset Management LLC is a venture capital firm located in Boston. The firm is a subsidiary of Moscow-based Maxwell Capital Group LLC. They manage the Maxwell Biotech Venture Fund, Russia's first venture fund focused on the medical and biotechnology sectors. The fund is one of the first venture funds formed with the participation of the Russian Venture Company (RVC), a fund-of-funds created by the Russian government to promote the development of the venture capital industry and an innovation-based economy.

Part of Biogen, Inc., Biogen GmbH is a pioneer in the field of neuroscience since 1978. The private company is based in Ismaning, Germany. Biogen focuses on research in therapeutic areas with a strong emphasis on difficult-to-treat diseases. The German company was founded in 1978 by Charles Weissman, Kenneth Murray, Heinz Schaller, Phillip Sharp, Walter Gilbert. The CEO is Michel Pericles Vounatsos.